论文部分内容阅读
目的:研究宣肺平喘胶囊对慢性阻塞性肺疾病(COPD)的作用机制。方法:SD健康大鼠60只,除正常组10只外,其余大鼠采用香烟烟熏联合气管内注射脂多糖方法建立COPD大鼠模型,造模成功后,随机分为宣肺平喘胶囊低、中、高剂量组(0.38,0.75,1.5 g·kg~(-1)),模型组,阳性药物组(地塞米松,0.09 mg·kg-1)。正常组和模型组以蒸馏水ig,阳性药物组以地塞米松混悬液ig,其余治疗组以宣肺平喘颗粒混悬液ig,时间30 d,每天1次。末次ig后,观测大鼠一般情况;取血清,酶连免疫吸附测定法(ELISA)检测血清中肿瘤坏死因子-α(TNF-α),血管内皮生长因子(VEGF),白细胞介素-8(IL-8),白细胞介素-1β(IL-1β)的含量,蛋白质免疫印迹(Western blot)检测大鼠肺组织血小板源生长因子-B(PDGF-B)蛋白的表达,检测大鼠支气管肺泡灌洗液(BALF)中白细胞计数和分类,同时进行苏木素-伊红(HE)染色,病理组织观察。结果:与正常组比较,模型组大鼠血清中TNF-α,IL-8,IL-1β含量增高,VEGF含量降低,肺组织PDGF-B含量增高,支气管肺泡灌洗液中白细胞总数增高,嗜中性粒细胞、淋巴细胞、肺泡巨噬细胞比例增高(P<0.05,P<0.01);与模型组比较,宣肺平喘胶囊各剂量组大鼠血清TNF-α,IL-8,IL-1β明显降低,VEGF明显增多,肺组织PDGF-B明显降低(P<0.05,P<0.01),支气管肺泡灌洗液中嗜中性粒细胞、淋巴细胞、肺泡巨噬细胞比例明显降低(P<0.05),宣肺平喘胶囊高剂量组和地塞米松组与模型组比较,支气管肺泡灌洗液中白细胞总数均明显降低(P<0.05,P<0.01)。结论:宣肺平喘胶囊能够降低COPD大鼠血清中的TNF-α,IL-8,IL-1β降低,降低肺组织中PDGF-B,增高血清中VEGF,高剂量组还可以降低BALF白细胞总数,作用机制有可能与减少炎症介质生成和释放,发挥抗炎作用,减轻气道表皮粘液分泌,抑制气道重塑有关。
Objective: To study the mechanism of Xuanfei Pingchuan Capsule on chronic obstructive pulmonary disease (COPD). Methods: Sixty healthy SD rats were divided into three groups: normal control group (n = 10), and the other rats were given cigarette smoke combined with intratracheal instillation of lipopolysaccharide (LPS) to establish a COPD rat model. (0.38,0.75,1.5 g · kg ~ (-1)), model group and positive drug group (dexamethasone, 0.09 mg · kg-1). Normal group and model group with distilled water ig, positive drug group with dexamethasone suspension ig, the rest of the treatment group to Xuanfei asthma particles suspension ig, time 30 d, day 1. After the last ig, the general situation of the rats was observed. Serum and enzyme linked immunosorbent assay (ELISA) were used to detect the levels of tumor necrosis factor-α (TNF-α), vascular endothelial growth factor (VEGF) and interleukin-8 IL-8, IL-1β, and Western blot were used to detect the expression of platelet-derived growth factor-B (PDGF-B) The white blood cell count and classification in lavage fluid (BALF) were determined by hematoxylin-eosin (HE) staining and histopathology. Results: Compared with the normal group, the levels of TNF-α, IL-8 and IL-1β in the serum of model group were increased, the content of VEGF was decreased, the content of PDGF-B in lung tissue was increased, the total number of leukocytes in bronchoalveolar lavage fluid was increased (P <0.05, P <0.01). Compared with the model group, the levels of serum TNF-α, IL-8 and IL- 1β and VEGF were significantly increased, and the level of PDGF-B in lung tissue was significantly decreased (P <0.05, P <0.01). The proportion of neutrophils, lymphocytes and alveolar macrophages in bronchoalveolar lavage fluid was significantly decreased (P < 0.05). Compared with the model group, the total number of leukocytes in bronchoalveolar lavage fluid of Xuanfei Pingchuan Capsule high-dose group and dexamethasone group were significantly decreased (P <0.05, P <0.01). Conclusion: Xuanfei Pingchuan Capsule can reduce the serum levels of TNF-α, IL-8 and IL-1β in COPD rats, reduce PDGF-B in lung tissue and increase serum VEGF. , The mechanism of action may be related to reducing the generation and release of inflammatory mediators, exerting anti-inflammatory effects, reducing mucus secretion in the airway epithelium and inhibiting airway remodeling.